Cargando…

Histologic transformation of lung cancer during pembrolizumab therapy: A case report

Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69‐year‐old man with stage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Xiaoyan, You, Yan, Zhang, Xiaotong, Wang, Hanping, Wang, Mengzhao, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049493/ https://www.ncbi.nlm.nih.gov/pubmed/31944570 http://dx.doi.org/10.1111/1759-7714.13312

Ejemplares similares

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
por: Si, Xiaoyan, et al.
Publicado: (2020)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease
por: Wang, Hanping, et al.
Publicado: (2019)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
por: Okeya, Komugi, et al.
Publicado: (2019)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
por: Si, Xiaoyan, et al.
Publicado: (2023)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score
por: Song, Peng, et al.
Publicado: (2020)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2020)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid
por: Zhang, Xiaoyan, et al.
Publicado: (2021)

A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review
por: Kakimoto, Tomoo, et al.
Publicado: (2019)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
por: Leow, Lowell, et al.
Publicado: (2023)

Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports
por: Shao, Yi, et al.
Publicado: (2020)

Histology transformation-mediated pathological atypism in small-cell lung cancer within the presence of chemotherapy: A case report
por: Ju, Qing, et al.
Publicado: (2021)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR ‐mutated non‐small‐cell lung cancer: A case report
por: Zhang, Meng, et al.
Publicado: (2022)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report
por: Zhang, Shuliang, et al.
Publicado: (2022)

Pembrolizumab: Various toxicities: case report
Publicado: (2021)

Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response
por: Shi, Yuequan, et al.
Publicado: (2021)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer
por: Kim, Kyung Woo, et al.
Publicado: (2021)

Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report
por: Tanaka, Sho, et al.
Publicado: (2020)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
por: Ni, Dan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0i7h0lbrilui221g77lq23nuqv